Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (DE:RGO)
FRANKFURT:RGO
Regeneron (RGO) Stock Price & Analysis
2 Followers
RGO Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€632.00 - €920.00
Previous Close€889.6
Volume0.00
Average Volume (3M)13.00
Market Cap
€99.33B
Enterprise Value€91.81B
Total Cash (Recent Filing)$10.84B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)28.5
Beta0.33
Next Earnings
Aug 01, 2024EPS Estimate
€9.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)31.24
Shares Outstanding110,185,503
10 Day Avg. Volume5
30 Day Avg. Volume13
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)4.28
Price to Sales (P/S)7.42
Price to Cash Flow (P/CF)24.50
P/FCF Ratio31.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.00
Enterprise Value/Gross Profit7.53
Enterprise Value/Ebitda19.56
Forecast
1Y Price Target
€974.41Price Target Upside9.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Regeneron News
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentSignificant pipeline optionality over the balance of the year with several potential catalysts could drive stock momentum.
Product PerformanceEylea HD sales come in ahead of consensus, showing a solid start despite competition.
Strategic InitiativesThe company announced a new share repurchase program to repurchase up to an additional $3.0B.
Bears Say
Competitive LandscapeThe company faces stronger competitive headwinds for key products, which may hinder market dominance and growth prospects.
Legal IssuesAllegations by the Department of Justice that the company fraudulently inflated drug prices could result in legal challenges and financial penalties.
Regulatory SetbacksA recent setback in the approval process for a key drug application raises concerns about potential delays in market entry and revenue streams.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.94% Insiders
34.04% Mutual Funds
41.99% Other Institutional Investors
21.03% Public Companies and
Individual Investors
RGO FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was €632.00 and its highest was €920.00 in the past 12 months.
What is Regeneron’s market cap?
Currently, no data Available
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Aug 01, 2024 which is in 75 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on May 02, 2024. The company reported €8.824 earnings per share for the quarter, missing the consensus estimate of €9.398 by -€0.574.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is €9.8.
How many shares outstanding does Regeneron have?
Regeneron has 108,367,355 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of €8.824 in its last earnings report, missing expectations of €9.398. Following the earnings report the stock price went up 2.849%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€974.41 (9.53% Upside)
€974.41 (9.53% Upside)
Blogger Sentiment
Bullish
DE:RGO Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $7.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.40%
12-Months-Change
Fundamentals
Return on Equity
15.28%
Trailing 12-Months
Asset Growth
14.34%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
RGO Company Deck
---
RGO Earnings Call
Q1 2024
0:00 / 0:00
---
RGO Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
RGO Stock 12 Month Forecast
Average Price Target
€974.41
▲(9.53% Upside)
Technical Analysis
Best Analysts Covering RGO
1 Year
1 Year Success Rate
20/21 ratings generated profit
1 Year Average Return
+17.80%
reiterated a buy rating 16 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 95.24% of your transactions generating a profit, with an average return of +17.80% per trade.
---